UNSPSC 51294401: Mezilamine

This classification denotes an antipsychotic agent with the molecular formula C11H18ClN5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V243ORA40X, chemically known as 2-pyridinamine, 4-chloro-n-methyl-6-(4-methyl-1-piperazinyl)-5-(methylthio)- but generally known as mezilamine, which bears US NIH Compound Identifier 68678. European Medicines Agency schedules Mezilamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08937MIG.

UNSPSC 51294401 Mezilamine, a Commodity code, does not align with the state and local procurement activity posted under it. The recent opportunities solicited under this code involve naloxone, drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which are mezilamine or related to its chemical classification. The code shows a mismatch between its nominal scope and the actual work state and local governments are buying under the code designation.

The three recent opportunities span health and human services procurement across Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS, response deadline July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building; the Texas Health and Human Services Commission issued an RFI (HHS0017013, response deadline April 3, 2026) to gather vendor capabilities regarding direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, response deadline March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products through authorized wholesalers for distribution across participating state and local government facilities, including Oregon. The MMCAP opportunity, evaluated 75 percent on price competitiveness, requires vendors to maintain relationships with at least two of three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards, with a two-year contract term beginning July 1, 2026.